📊 ORMP Key Takeaways
Is Oramed Pharmaceuticals Inc.. (ORMP) a Good Investment?
Oramed is a pre-commercial biotech company with concerning operational fundamentals: negative operating cash flow of -$2.9M on minimal $2.0M revenue, deep operating losses (-182.9% margin), and significant cash burn despite strong balance sheet liquidity. The anomalously high net income ($38.3M on $2.0M revenue) indicates large non-operating gains masking weak core operations, raising sustainability questions.
Headline profitability is driven by non-operating gains, while core operations remain weak with near-zero gross margin and sizable operating losses. Liquidity is solid, but meaningful long-term debt alongside negative interest coverage and persistent cash burn undermine sustainability. Until margins and operating cash flow improve, fundamentals do not justify a positive stance.
Oramed Pharmaceuticals Inc.. Key Strengths (ORMP)
- Strong balance sheet with low liabilities ($502.7K) and high stockholders' equity ($238.3M)
- Excellent liquidity position with 6.45x current ratio and $13.2M cash
- Revenue growth of 49.3% YoY demonstrates market traction despite minimal absolute scale
- Conservative leverage at 0.31x debt-to-equity ratio
- Robust liquidity (current/quick 6.98x) with $45.95M cash
- Revenue growth (+49.3% YoY) albeit from a small base
- Moderate debt-to-equity (0.37x) relative to asset base
ORMP Stock Risks: Oramed Pharmaceuticals Inc.. Investment Risks
- Severe operational cash burn of -$2.9M annually with negative free cash flow and no path to profitability visible
- Unexplained massive divergence between $38.3M net income and -$2.9M operating cash flow suggests non-recurring gains masking fundamental operational distress
- Operating margin of -182.9% indicates business model not yet scaled to break-even; tiny $2.0M revenue base insufficient to support operations
- Early-stage biotech with execution risk on clinical trials and regulatory approvals; cash runway limited if cash burn accelerates
- Extremely low gross margin (0.7%) and large operating loss
- Negative operating cash flow and interest coverage
- Earnings quality concerns; net income driven by non-operating items and data inconsistencies (liabilities vs debt)
Key Metrics to Watch
- Operating cash flow trend and runway until cash depletion at current burn rate
- Gross margin expansion as revenue scales and commercialization progresses
- Operating income path to profitability and sustainability of non-operating gains
- Pipeline advancement milestones and regulatory approval status for lead candidates
- Operating cash flow (burn rate)
- Gross margin trend
Oramed Pharmaceuticals Inc.. (ORMP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.45x current ratio provides a solid financial cushion.
ORMP Profit Margin, ROE & Profitability Analysis
ORMP vs Healthcare Sector: How Oramed Pharmaceuticals Inc.. Compares
How Oramed Pharmaceuticals Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Oramed Pharmaceuticals Inc.. Stock Overvalued? ORMP Valuation Analysis 2026
Based on fundamental analysis, Oramed Pharmaceuticals Inc.. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Oramed Pharmaceuticals Inc.. Balance Sheet: ORMP Debt, Cash & Liquidity
ORMP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Oramed Pharmaceuticals Inc..'s revenue has declined by 26% over the 5-year period, indicating business contraction. The most recent EPS of $-0.48 indicates the company is currently unprofitable.
ORMP Revenue Growth, EPS Growth & YoY Performance
ORMP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.0M | -$7.6M | $-0.19 |
| Q3 2025 | $2.0M | -$8.9M | $-0.22 |
| Q2 2025 | $2.0M | $5.6M | $0.13 |
| Q1 2025 | $2.0M | $1.5M | $0.04 |
| Q3 2024 | $1.3M | -$3.2M | $-0.08 |
| Q2 2024 | $674.0K | -$1.2M | $-0.03 |
| Q1 2024 | $666.0K | $1.5M | $0.04 |
| Q3 2023 | $682.0K | -$3.2M | $0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Oramed Pharmaceuticals Inc.. Dividends, Buybacks & Capital Allocation
ORMP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Oramed Pharmaceuticals Inc.. (CIK: 0001176309)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ORMP
What is the AI rating for ORMP?
Oramed Pharmaceuticals Inc.. (ORMP) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 56% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ORMP's key strengths?
Claude: Strong balance sheet with low liabilities ($502.7K) and high stockholders' equity ($238.3M). Excellent liquidity position with 6.45x current ratio and $13.2M cash. ChatGPT: Robust liquidity (current/quick 6.98x) with $45.95M cash. Revenue growth (+49.3% YoY) albeit from a small base.
What are the risks of investing in ORMP?
Claude: Severe operational cash burn of -$2.9M annually with negative free cash flow and no path to profitability visible. Unexplained massive divergence between $38.3M net income and -$2.9M operating cash flow suggests non-recurring gains masking fundamental operational distress. ChatGPT: Extremely low gross margin (0.7%) and large operating loss. Negative operating cash flow and interest coverage.
What is ORMP's revenue and growth?
Oramed Pharmaceuticals Inc.. reported revenue of $2.0M.
Does ORMP pay dividends?
Oramed Pharmaceuticals Inc.. pays dividends, with $10.4M distributed to shareholders in the trailing twelve months.
Where can I find ORMP SEC filings?
Official SEC filings for Oramed Pharmaceuticals Inc.. (CIK: 0001176309) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ORMP's EPS?
Oramed Pharmaceuticals Inc.. has a diluted EPS of $0.91.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ORMP's fundamental grade?
Based on our AI fundamental analysis in May 2026, Oramed Pharmaceuticals Inc.. has a C grade with 56% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ORMP stock overvalued or undervalued?
Valuation metrics for ORMP: ROE of 16.1% (sector avg: 15%), net margin of 1,915.5% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
What is ORMP's AI grade for 2026?
Our dual AI analysis gives Oramed Pharmaceuticals Inc.. a combined C grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ORMP's free cash flow?
Oramed Pharmaceuticals Inc..'s operating cash flow is $-2.9M, with capital expenditures of $5.0K. FCF margin is -146.0%.
How does ORMP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 1,915.5% (avg: 12%), ROE 16.1% (avg: 15%), current ratio 6.45 (avg: 2).